trending Market Intelligence /marketintelligence/en/news-insights/trending/7mrFhSMQnizmXCY1lDkbAw2 content esgSubNav
In This List

Principia Biopharma prices $210M common stock offering

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Principia Biopharma prices $210M common stock offering

Principia Biopharma Inc. priced its underwritten public offering of 7.5 million common shares at $28 each.

The South San Francisco, Calif.-based company also granted underwriters a 30-day option to buy up to 1,125,000 additional common shares at the same price.

Principia expects $210 million in gross proceeds from the offering.

The offer is expected to close on or about Oct. 18.

BofA Merrill Lynch, SVB Leerink, and Wells Fargo Securities are acting as joint book-running managers for the offering, while Baird is lead manager, while H.C. Wainwright & Co. is co-manager for the offer.

Principia Biopharma Inc. develops therapies for immunology and oncology.